Anti-S. typhimurium Monoclonal antibody, Clone 7456

BACKGROUND Slightly acidic electrolyzed water (SAEW) has been shown to offer a promising alternative for the inactivation of bacteria on egg surfaces, but the cuticle of the egg is damaged during this disinfection process. However, if SAEW disinfection is followed by chitosan (CS) coating treatment, this will construct a new membrane and prevent the loss of moisture and carbon dioxide through the damaged cuticle. Hence, the objective of this study was to investigate the efficacy of SAEW disinfection followed by CS coating treatment for improving the internal quality of eggs during 6 weeks of storage at 25 degrees C. RESULTS Scanning electron microscopy revealed that SAEW-treated eggs had deeper and wider cracks than control eggs stored between 0 and 21 days. Moreover, the depth and width of the cracks in the uncoated eggs increased as storage time increased. However, the CS coating method was successfully used on SAEW-disinfected eggs to construct a barrier against the negative effects of shell damage. After 6 weeks of storage at 25 degrees C, the yolk index, albumen pH, Haugh unit value and weight loss value of the SAEW + CS group were 0.31%, 9.01%, 63.72% and 5.35%, respectively. CONCLUSIONS A combination of SAEW and CS was more effective at maintaining internal egg quality than SAEW or CS treatments alone during storage. (c) 2020 Society of Chemical Industry

Monophosphoryl lipid A (MPL(R)) is the first non-alum vaccine adjuvant to achieve widespread clinical and market acceptance, a remarkable achievement given that it is manufactured from a Salmonella enterica endotoxin. To understand how MPL(R) successfully balanced the dual mandate of vaccine design-low reactogenicity with high efficacy-clinical- and research-grade MPL was evaluated in human and mouse cell systems. Stimulatory dose response curves revealed that most preparations of MPL are much more active in mouse than in human cell systems, and that the limited efficacy observed in human cells correlated with TLR4 inhibitory activity that resulted in a partial agonist profile. Further analysis of the major components of MPL(R) adjuvant prepared synthetically identified two structural variants that functioned as competitive antagonists of human TLR4. A partial agonist profile could be recapitulated and manipulated by spiking synthetic agonists with synthetic antagonists to achieve a broad dose range over which TLR4 stimulation could be constrained below a desired threshold. This report thus identifies mixed agonist-antagonist activity as an additional mechanism by which MPL(R) adjuvant is detoxified, relative to its parental LPS, to render it safe for use in prophylactic vaccines.